{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T17:26:51Z","timestamp":1789925211056,"version":"4.0.1"},"reference-count":105,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"am","delay-in-days":343,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.clml.2025.02.003","type":"journal-article","created":{"date-parts":[[2025,2,16]],"date-time":"2025-02-16T03:42:32Z","timestamp":1739677352000},"page":"484-493","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["SOHO State of the Art Updates and Next Questions | Challenging Scenarios in the Management of Myeloproliferative Neoplasms"],"prefix":"10.1016","volume":"25","author":[{"given":"Joseph","family":"Cannova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiv","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0296-8686","authenticated-orcid":false,"given":"Anand A.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.clml.2025.02.003_bib0001","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1182\/blood-2016-10-695957","article-title":"Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms","volume":"129","author":"Rumi","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.02.003_bib0002","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1182\/hematology.2020000129","article-title":"Genomics of MPN progression","volume":"2020","author":"Patel","year":"2020","journal-title":"Hematol Am Soc Hematol Educ Prog"},{"key":"10.1016\/j.clml.2025.02.003_bib0003","article-title":"Prevention and treatment of transformation of myeloproliferative neoplasms to acute myeloid leukemia","volume":"24","author":"Patel","year":"2024","journal-title":"Haematologica"},{"issue":"20","key":"10.1016\/j.clml.2025.02.003_bib0004","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1182\/blood.2023021218","article-title":"How I treat transplant-eligible patients with myelofibrosis","volume":"142","author":"Kr\u00f6ger","year":"2023","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.clml.2025.02.003_bib0005","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2025.02.003_bib0006","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2025.02.003_bib0007","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.clml.2025.02.003_bib0008","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2025.02.003_bib0009","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","article-title":"MIPSS70: Mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis","volume":"36","author":"Guglielmelli","year":"2018","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.clml.2025.02.003_bib0010","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","article-title":"MIPSS70+ Version 2.0: mutation and karyotype-enhanced International prognostic scoring system for primary myelofibrosis","volume":"36","author":"Tefferi","year":"2018","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.clml.2025.02.003_bib0011","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and personalized prognosis in myeloproliferative neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clml.2025.02.003_bib0012","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1182\/bloodadvances.2020003444","article-title":"Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study","volume":"5","author":"Luque","year":"2021","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.clml.2025.02.003_bib0013","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41375-019-0603-9","article-title":"Prognostic impact of RAS-pathway mutations in patients with myelofibrosis","volume":"34","author":"Santos","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2025.02.003_bib0014","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/ajh.27136","article-title":"The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70\/plus\/plus v2.0) for primary myelofibrosis","volume":"99","author":"Loscocco","year":"2024","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.clml.2025.02.003_bib0015","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/ajh.27274","article-title":"2024 update on allogeneic hematopoietic stem cell transplant for myelofibrosis: a review of current data and applications on risk stratification and management","volume":"99","author":"Ali","year":"2024","journal-title":"Am J Hematol"},{"issue":"21","key":"10.1016\/j.clml.2025.02.003_bib0016","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1182\/blood-2014-10-608315","article-title":"Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis","volume":"125","author":"Kr\u00f6ger","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2025.02.003_bib0017","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/bloodadvances.2019001084","article-title":"Survival following allogeneic transplant in patients with myelofibrosis","volume":"4","author":"Gowin","year":"2020","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.clml.2025.02.003_bib0018","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.bbmt.2017.03.034","article-title":"Impact of molecular genetics on outcome in myelofibrosis patients after allogeneic stem cell transplantation","volume":"23","author":"Kr\u00f6ger","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"23","key":"10.1016\/j.clml.2025.02.003_bib0019","first-page":"2901","article-title":"Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation","volume":"141","author":"Gagelmann","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2025.02.003_bib0020","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1182\/bloodadvances.2024014368","article-title":"Role of molecular alterations in transplantation decisions for patients with primary myelofibrosis","volume":"9","author":"Luque","year":"2025","journal-title":"Blood Adv"},{"issue":"20","key":"10.1016\/j.clml.2025.02.003_bib0021","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1182\/blood-2018-12-890889","article-title":"Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation","volume":"133","author":"Gagelmann","year":"2019","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2025.02.003_bib0022","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/bloodadvances.2021006889","article-title":"A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis","volume":"6","author":"Maffioli","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.clml.2025.02.003_bib0023","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ajh.26020","volume":"96","author":"Polverelli","year":"2021","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.clml.2025.02.003_bib0024","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/S2352-3026(22)00330-1","article-title":"Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a position paper on behalf of the chronic malignancies working party of the EBMT","volume":"10","author":"Polverelli","year":"2023","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1016\/j.clml.2025.02.003_bib0025","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00277-017-3194-4","article-title":"Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation","volume":"97","author":"Kuykendall","year":"2018","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.clml.2025.02.003_bib0026","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-017-0417-z","article-title":"Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"6","key":"10.1016\/j.clml.2025.02.003_bib0027","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11899-020-00596-z","article-title":"The next generation of JAK inhibitors: an update on fedratinib, momelotonib, and pacritinib","volume":"15","author":"Patel","year":"2020","journal-title":"Curr Hematol Malig Rep"},{"issue":"7","key":"10.1016\/j.clml.2025.02.003_bib0028","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","article-title":"Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study","volume":"4","author":"Harrison","year":"2017","journal-title":"Lancet Haematol"},{"issue":"6","key":"10.1016\/j.clml.2025.02.003_bib0029","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/ajh.25777","article-title":"Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: an updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure","volume":"95","author":"Harrison","year":"2020","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.clml.2025.02.003_bib0030","doi-asserted-by":"crossref","first-page":"e729","DOI":"10.1016\/S2352-3026(24)00212-6","article-title":"Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"11","author":"Harrison","year":"2024","journal-title":"Lancet Haematol"},{"issue":"5","key":"10.1016\/j.clml.2025.02.003_bib0031","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","article-title":"Pacritinib vs best available therapy, including Ruxolitinib, in patients with myelofibrosis: a randomized clinical trial","volume":"4","author":"Mascarenhas","year":"2018","journal-title":"JAMA Oncol"},{"issue":"22","key":"10.1016\/j.clml.2025.02.003_bib0032","doi-asserted-by":"crossref","first-page":"5825","DOI":"10.1182\/bloodadvances.2020003314","article-title":"Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis","volume":"4","author":"Gerds","year":"2020","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.clml.2025.02.003_bib0033","doi-asserted-by":"crossref","first-page":"e735","DOI":"10.1016\/S2352-3026(23)00174-6","article-title":"Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study","volume":"10","author":"Gerds","year":"2023","journal-title":"Lancet Haematol"},{"issue":"6","key":"10.1016\/j.clml.2025.02.003_bib0034","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s00277-020-04002-9","article-title":"Management of myelofibrosis after ruxolitinib failure","volume":"99","author":"Harrison","year":"2020","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.clml.2025.02.003_bib0035","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/cncr.22021","article-title":"Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic","volume":"107","author":"Mesa","year":"2006","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.clml.2025.02.003_bib0036","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1182\/blood.V95.7.2226","article-title":"Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients","volume":"95","author":"Tefferi","year":"2000","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2025.02.003_bib0037","first-page":"359","article-title":"Risks and benefits of splenectomy in myelofibrosis: an analysis of 39 cases","volume":"36","author":"Lafaye","year":"1994","journal-title":"Nouv Rev Fr Hematol"},{"issue":"6","key":"10.1016\/j.clml.2025.02.003_bib0038","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.bbmt.2017.03.002","article-title":"The impact of splenectomy in myelofibrosis patients before allogeneic hematopoietic stem cell transplantation","volume":"23","author":"Robin","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.clml.2025.02.003_bib0039","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s004649901040","article-title":"Effect of spleen size on splenectomy outcome. A comparison of open and laparoscopic surgery","volume":"13","author":"Targarona","year":"1999","journal-title":"Surg Endosc"},{"issue":"2","key":"10.1016\/j.clml.2025.02.003_bib0040","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/01.sla.0000080826.97026.d8","article-title":"Massive splenomegaly is associated with significant morbidity after laparoscopic splenectomy","volume":"238","author":"Patel","year":"2003","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.clml.2025.02.003_bib0041","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00268-020-05839-x","article-title":"Outcomes of laparoscopic splenectomy for treatment of splenomegaly: a systematic review and meta-analysis","volume":"45","author":"Rodr\u00edguez-Luna","year":"2021","journal-title":"World J Surg"},{"issue":"12","key":"10.1016\/j.clml.2025.02.003_bib0042","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1080\/10428194.2017.1321747","article-title":"Low-dose splenic irradiation prior to hematopoietic cell transplantation in hypersplenic patients with myelofibrosis","volume":"58","author":"Kalman","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.clml.2025.02.003_bib0043","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s12032-019-1245-5","article-title":"Splenic irradiation before allogeneic stem cell transplantation for myelofibrosis","volume":"36","author":"Helbig","year":"2019","journal-title":"Med Oncol"},{"issue":"5","key":"10.1016\/j.clml.2025.02.003_bib0044","article-title":"Pretransplant splenic irradiation in patients with myeloproliferative neoplasms","volume":"7","author":"Ponce","year":"2022","journal-title":"Adv Radiat Oncol"},{"issue":"5","key":"10.1016\/j.clml.2025.02.003_bib0045","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/ajh.27252","article-title":"Splenic irradiation for myelofibrosis prior to hematopoietic cell transplantation: a global collaborative analysis","volume":"99","author":"Gagelmann","year":"2024","journal-title":"Am J Hematol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.02.003_bib0046","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1182\/blood-2023-173509","article-title":"Transform-1: a randomized, double-blind, placebo-controlled, multicenter, international phase 3 study of Navitoclax in combination with Ruxolitinib versus Ruxolitinib plus Placebo in patients with untreated myelofibrosis","volume":"142","author":"Pemmaraju","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.02.003_bib0047","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1182\/blood-2023-179141","article-title":"Pelabresib in combination with Ruxolitinib for Janus Kinase inhibitor treatment-na\u00efve patients with myelofibrosis: results of the MANIFEST-2 randomized, double-blind, phase 3 study","volume":"142","author":"Rampal","year":"2023","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.clml.2025.02.003_bib0048","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2025.02.003_bib0049","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000204873","article-title":"Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients","volume":"85","author":"Cervantes","year":"1991","journal-title":"Acta Haematol"},{"issue":"11","key":"10.1016\/j.clml.2025.02.003_bib0050","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2025.02.003_bib0051","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.clml.2025.02.003_bib0052","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41408-018-0095-2","article-title":"Validation of the WHO-defined 20% circulating blasts threshold for diagnosis of leukemic transformation in primary myelofibrosis","volume":"8","author":"Mudireddy","year":"2018","journal-title":"Blood Cancer J"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.02.003_bib0053","doi-asserted-by":"crossref","first-page":"6422","DOI":"10.1182\/blood-2023-184761","article-title":"The diagnostic value of circulating blasts in patients with myeloproliferative neoplasms in accelerated or blast phase","volume":"142","author":"Yacoub","year":"2023","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2025.02.003_bib0054","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.clml.2023.01.011","article-title":"SOHO state of the art updates and next questions | accelerated phase of MPN: what it is and what to do about it","volume":"23","author":"Patel","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.clml.2025.02.003_bib0055","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood.2019000943","article-title":"Leukemia secondary to myeloproliferative neoplasms","volume":"136","author":"Dunbar","year":"2020","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2025.02.003_bib0056","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s41375-018-0019-y","article-title":"Blast phase myeloproliferative neoplasm: mayo-AGIMM study of 410 patients from two separate cohorts","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.clml.2025.02.003_bib0057","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1182\/blood-2018-03-785907","article-title":"How I treat the blast phase of Philadelphia chromosome-negative myeloproliferative neoplasms","volume":"132","author":"Odenike","year":"2018","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2025.02.003_bib0058","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1038\/s41375-020-0778-0","article-title":"A phase 1\/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia","volume":"34","author":"Bose","year":"2020","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.02.003_bib0059","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1182\/blood-2020-138437","volume":"136","author":"Drummond","year":"2020","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.clml.2025.02.003_bib0060","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1182\/bloodadvances.2018019661","article-title":"Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms","volume":"2","author":"Rampal","year":"2018","journal-title":"Blood Adv"},{"issue":"20","key":"10.1016\/j.clml.2025.02.003_bib0061","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1182\/bloodadvances.2020002119","article-title":"Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase","volume":"4","author":"Mascarenhas","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.clml.2025.02.003_bib0062","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/bjh.18853","article-title":"Combination of azacitidine, venetoclax and ruxolitinib in blast phase myeloproliferative neoplasms","volume":"202","author":"Systchenko","year":"2023","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.clml.2025.02.003_bib0063","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1158\/2643-3230.BCD-22-0189","article-title":"Next-generation JAK2 inhibitors for the treatment of myeloproliferative neoplasms: lessons from structure-based drug discovery approaches","volume":"4","author":"Nair","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"7","key":"10.1016\/j.clml.2025.02.003_bib0064","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.02.003_bib0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106456","article-title":"Venetoclax and hypomethylating agent combination therapy in acute myeloid leukemia secondary to a myeloproliferative neoplasm","volume":"98","author":"Tremblay","year":"2020","journal-title":"Leuk Res"},{"issue":"5","key":"10.1016\/j.clml.2025.02.003_bib0066","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.3324\/haematol.2022.282019","article-title":"Predictors of response to venetoclax plus hypomethylating agent therapy and survival in blast-phase myeloproliferative neoplasm","volume":"108","author":"Gangat","year":"2023","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.clml.2025.02.003_bib0067","doi-asserted-by":"crossref","first-page":"E7","DOI":"10.1002\/ajh.26381","article-title":"Multicenter evaluation of efficacy and toxicity of venetoclax-based combinations in patients with accelerated and blast phase myeloproliferative neoplasms","volume":"97","author":"King","year":"2022","journal-title":"Am J Hematol"},{"issue":"13","key":"10.1016\/j.clml.2025.02.003_bib0068","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1182\/bloodadvances.2024012880","article-title":"Treatment approach and outcomes of patients with accelerated\/blast-phase myeloproliferative neoplasms in the current era","volume":"8","author":"Patel","year":"2024","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.clml.2025.02.003_bib0069","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1182\/bloodadvances.2020003934","article-title":"Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs","volume":"5","author":"Masarova","year":"2021","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.clml.2025.02.003_bib0070","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJMc0910063","article-title":"Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms","volume":"362","author":"Green","year":"2010","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.clml.2025.02.003_bib0071","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/leu.2010.77","article-title":"IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms","volume":"24","author":"Pardanani","year":"2010","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.clml.2025.02.003_bib0072","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1158\/0008-5472.CAN-09-3783","article-title":"Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias","volume":"70","author":"Abdel-Wahab","year":"2010","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.clml.2025.02.003_bib0073","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/ajh.24973","article-title":"Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms","volume":"93","author":"Venton","year":"2018","journal-title":"Am J Hematol"},{"issue":"20","key":"10.1016\/j.clml.2025.02.003_bib0074","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1182\/bloodadvances.2018021469","article-title":"The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes","volume":"2","author":"McNamara","year":"2018","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.clml.2025.02.003_bib0075","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1182\/bloodadvances.2018015875","article-title":"Targeted next-generation sequencing in blast phase myeloproliferative neoplasms","volume":"2","author":"Lasho","year":"2018","journal-title":"Blood Adv"},{"issue":"25","key":"10.1016\/j.clml.2025.02.003_bib0076","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with Ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2025.02.003_bib0077","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1016\/S2352-3026(22)00292-7","article-title":"Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1\/2 trial","volume":"10","author":"Watts","year":"2023","journal-title":"Lancet Haematol"},{"issue":"6","key":"10.1016\/j.clml.2025.02.003_bib0078","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.clml.2025.02.003_bib0079","doi-asserted-by":"crossref","first-page":"5336","DOI":"10.1182\/bloodadvances.2020001528","article-title":"Outcome of patients with IDH1\/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors","volume":"4","author":"Chifotides","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.clml.2025.02.003_bib0080","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1111\/bjh.16709","article-title":"Clinical outcomes of IDH2-mutated advanced-phase ph-negative myeloproliferative neoplasms treated with enasidenib","volume":"190","author":"Patel","year":"2020","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.clml.2025.02.003_bib0081","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2025.02.003_bib0082","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.leukres.2012.08.013","article-title":"Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium","volume":"36","author":"Mascarenhas","year":"2012","journal-title":"Leuk Res"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.02.003_bib0083","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1182\/blood-2024-197898","article-title":"Outcomes of patients with IDH1\/2 mutated accelerated\/blast-phase myeloproliferative neoplasms in the era of IDH inhibitors","volume":"144","author":"Goldberg","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2025.02.003_bib0084","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1111\/bjh.19027","article-title":"IDH1\/2 inhibitor monotherapy in blast-phase myeloproliferative neoplasms: a multicentre experience","volume":"203","author":"Gangat","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2025.02.003_bib0085","article-title":"Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasm","author":"De Botton","year":"2024","journal-title":"Br J Haematol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.02.003_bib0086","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1182\/blood-2022-164678","article-title":"Molecularly targeted combination therapy for advanced phase myeloproliferative neoplasm: MPN-RC 119","volume":"140","author":"Bar-Natan","year":"2022","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.clml.2025.02.003_bib0087","doi-asserted-by":"crossref","first-page":"10978","DOI":"10.1111\/jcmm.15730","article-title":"Bcl-xL represents a therapeutic target in Philadelphia negative myeloproliferative neoplasms","volume":"24","author":"Petiti","year":"2020","journal-title":"J Cell Mol Med"},{"issue":"13","key":"10.1016\/j.clml.2025.02.003_bib0088","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1182\/blood.2021011094","article-title":"Erythroid\/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia","volume":"141","author":"Kuusanm\u00e4ki","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.02.003_bib0089","doi-asserted-by":"crossref","first-page":"4580","DOI":"10.1182\/blood-2024-198284","article-title":"Dual BCLxL and BCL2 inhibition with navitoclax (NAV), venetoclax (VEN), and decitabine (DEC) for advanced myeloid neoplasms (MN): safety and biological activity in a phase 1 study","volume":"144","author":"Chen","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.02.003_bib0090","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1182\/blood-2014-04-569525","article-title":"Lysine-specific demethylase 1 (LSD1) in hematopoietic and lymphoid neoplasms","volume":"124","author":"Niebel","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2025.02.003_bib0091","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1097\/HS9.0000000000000054","article-title":"LSD1 Inhibition prolongs survival in mouse models of MPN by selectively targeting the disease clone","volume":"2","author":"Jutzi","year":"2018","journal-title":"Hemasphere"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.02.003_bib0092","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1182\/blood-2020-140186","article-title":"LSD1 Inhibitor CPI-482 shows efficacy and prolongs survival in mouse models of AML and post-MPN AML in the context of constitutive JAK-STAT pathway activation","volume":"136","author":"Rampal","year":"2020","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2025.02.003_bib0093","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41408-021-00487-3","article-title":"Superior efficacy of co-targeting GFI1\/KDM1A and BRD4 against AML and post-MPN secondary AML cells","volume":"11","author":"Fiskus","year":"2021","journal-title":"Blood Cancer J"},{"issue":"36","key":"10.1016\/j.clml.2025.02.003_bib0094","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1200\/JCO.19.03250","article-title":"First-in-Human phase I study of Iadademstat (ORY-1001): A First-in-class lysine-specific histone demethylase 1A inhibitor, in relapsed or refractory acute myeloid leukemia","volume":"38","author":"Salamero","year":"2020","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clml.2025.02.003_bib0095","doi-asserted-by":"crossref","first-page":"e487","DOI":"10.1016\/S2352-3026(24)00132-7","article-title":"Iadademstat in combination with azacitidine in patients with newly diagnosed acute myeloid leukaemia (ALICE): an open-label, phase 2a dose-finding study","volume":"11","author":"Salamero","year":"2024","journal-title":"Lancet Haematol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.02.003_bib0096","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1182\/blood-2021-148210","article-title":"A phase 2 study of the LSD1 inhibitor img-7289 (bomedemstat) for the treatment of essential thrombocythemia (ET)","volume":"138","author":"Palandri","year":"2021","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.clml.2025.02.003_bib0097","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1182\/blood-2019-123244","article-title":"A phase 2a study of the LSD1 inhibitor img-7289 (bomedemstat) for the treatment of myelofibrosis","volume":"134","author":"Pettit","year":"2019","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.02.003_bib0098","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1182\/blood-2023-181971","article-title":"Phase 2 study to assess the safety and efficacy of bomedemstat (MK3543) in combination with ruxolitinib in patients with myelofibrosis","volume":"142","author":"Gill","year":"2023","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2025.02.003_bib0099","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/leu.2016.260","article-title":"BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells","volume":"31","author":"Saenz","year":"2017","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.clml.2025.02.003_bib0100","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood.2024026388","article-title":"Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML","volume":"145","author":"Fiskus","year":"2025","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2025.02.003_bib0101","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.bbmt.2019.01.002","article-title":"Impact of high-molecular-risk mutations on transplantation outcomes in patients with myelofibrosis","volume":"25","author":"Tamari","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.clml.2025.02.003_bib0102","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1182\/bloodadvances.2018026658","article-title":"MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu\/Mel conditioning regimen","volume":"3","author":"Ali","year":"2019","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.clml.2025.02.003_bib0103","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.bbmt.2020.03.007","article-title":"Targeted sequencing improves DIPSS-plus prognostic scoring in myelofibrosis patients undergoing allogeneic transplantation","volume":"26","author":"Stevens","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.clml.2025.02.003_bib0104","doi-asserted-by":"crossref","first-page":"259.e1","DOI":"10.1016\/j.jtct.2022.02.004","article-title":"Post-transplantation cyclophosphamide-based graft- versus-host disease prophylaxis with nonmyeloablative conditioning for blood or marrow transplantation for myelofibrosis","volume":"28","author":"Jain","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"12","key":"10.1016\/j.clml.2025.02.003_bib0105","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/s41409-023-02094-1","article-title":"Allogeneic hematopoietic cell transplantation in patients with CALR-mutated myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT","volume":"58","author":"Hern\u00e1ndez-Boluda","year":"2023","journal-title":"Bone Marrow Transplant"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025000655?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025000655?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T13:51:59Z","timestamp":1749477119000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025000655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":105,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2152265025000655"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.02.003","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | Challenging Scenarios in the Management of Myeloproliferative Neoplasms","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}